A New Milestone for Psoriatic Arthritis Care The U.S. Food and Drug Administration (FDA) has officially approved Ilumya (tildrakizumab-asmn) for the treatment of adults living with active psoriatic arthritis (PsA). This approval provides a significant new therapeutic option for patients managing this complex, inflammatory condition. Understanding Ilumya Ilumya is a humanized interleukin-23 (IL-23) p19 subunit…